Kidney Cancer Symposium 2017: Atezolizumab With Bevacizumab in Untreated Metastatic Kidney Cancer
In treatment-naive patients with metastatic renal cell carcinoma, the combination of atezolizumab and bevacizumab resulted in longer progression-free survival than atezolizumab alone or sunitinib alone, particularly among programmed cell death ligand 1 (PD-L1)–positive patients. These data from the phase II IMmotion150 trial (ClinicalTrials.gov identifier NCT01984242) were presented by Sumanta Kumar Pal, MD, of City of Hope in Duarte, California, at the 2017 International Kidney Cancer Symposium in Miami.
Untreated patients were randomized to receive intravenous atezolizumab at 1200 mg once every 3 weeks plus intravenous bevacizumab at 15 mg/kg once every 3 weeks; intravenous atezolizumab alone at 1200 mg once every 3 weeks; or oral sunitinib alone at 50 mg once daily for 4 weeks, followed by 2 weeks off treatment.
After a median follow-up of 25.7 months, the results were consistent with those from the primary analysis (median follow-up of 20.7 months), showing a clinically meaningful benefit in both independent review facility– and investigator-assessed progression-free survival with atezolizumab plus bevacizumab in PD-L1–positive patients. No new safety signals were reported with the combination therapy.
The clinical benefit of atezolizumab plus bevacizumab versus sunitinib in this patient population is undergoing further evaluation in the ongoing phase III IMmotion151 trial (NCT02420821).